TME Pharma N.V.

ALTME · PA · Healthcare / Biotechnology

0.1054EUR-0.01 (-7.05%)

Price History

Full chart

Market Stats

Previous Close0.1134

Open0.1128

Day Range0.1054 – 0.1128

52-Week Range0.049 – 0.1746

Volume676.65K

Market Cap9.78M

P/E (TTM)0.00

Forward P/E1.07

EPS-0.03

Dividend Yield0.00%

Beta0.76

50-Day Avg0.0974

200-Day Avg0.0794

About

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is headquartered in Berlin, Germany.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Diede Mink van den Ouden
Employees12
HeadquartersMax-Dohrn-Strasse 8-10, Berlin, Germany, 10589, France
Websitehttps://www.tmepharma.com

Leadership

Mr. Diede Mink van den OudenCEO & Member of Management Board · b. 1981
Dr. Aram Mangasarian M.B.A., Ph.D.Chief Scientific Officer & Member of Management Board · b. 1970
Dr. Jarl Ulf Jungnelius M.D., Ph.D.Chief Medical Officer & Member of Management Board · b. 1951

Financials

Income Statement

Currency: EUR	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	25.00K	43.00K	83.00K	234.00K	0	154	35	33.00K	0	17.00K	19.00K	0
Growth (%)	-	+72.00%	+93.02%	+181.93%	-100.00%	-	-77.27%	+94185.71%	-100.00%	-	+11.76%	-100.00%
Cost of Revenue	3.68M	2.64M	1.46M	959.00K	982.00K	1.03M	63.00K	66.00K	92.00K	144.00K	78.00K	8.00K
Gross Profit	-3.65M	-2.60M	-1.38M	-725.00K	-982.00K	-1.03M	-62.97K	-65.97K	-92.00K	-127.00K	-78.00K	-8.00K
Gross Margin	-14612.00%	-6044.19%	-1657.83%	-309.83%	-	-668081.82%	-179900.00%	-199.90%	-	-747.06%	-410.53%	-
Operating Expense	9.51M	12.23M	7.22M	4.00M	3.38M	2.92M	5.71M	13.20M	11.94M	5.50M	5.20M	2.90M
Operating Income	-13.17M	-14.83M	-8.60M	-4.73M	-4.37M	-3.95M	-5.77M	-13.27M	-12.03M	-5.62M	-5.28M	-2.91M
Operating Margin	-52664.00%	-34488.37%	-10360.24%	-2021.37%	-	-2563636.36%	-16482857.14%	-40203.03%	-	-33082.35%	-27773.68%	-
EBITDA	-12.88M	-14.61M	-8.44M	-3.68M	-3.96M	-810.00K	-5.29M	-12.88M	-11.63M	-5.07M	-5.25M	-2.90M
EBITDA Margin	-51536.00%	-33983.72%	-10162.65%	-1573.50%	-	-525974.03%	-15108571.43%	-39036.36%	-	-29835.29%	-27605.26%	-
Net Income	-13.80M	-16.10M	-10.75M	-5.38M	-10.73M	-861.00K	-10.40M	-14.45M	-15.13M	-6.74M	-5.72M	-3.29M
Net Income Margin	-55192.00%	-37446.51%	-12948.19%	-2301.28%	-	-559090.91%	-29728571.43%	-43793.94%	-	-39623.53%	-30115.79%	-
R&D	1.50M	906.00K	1.03M	402.00K	479.00K	496.00K	4.02M	10.66M	8.15M	2.65M	2.30M	1.36M
R&D as % of Total Revenue	6000.00%	2106.98%	1238.55%	171.79%	-	322077.92%	11477142.86%	32293.94%	-	15600.00%	12084.21%	-
Interest Expense	632.00K	1.29M	2.13M	1.68M	6.76M	3.00K	5.05M	1.50M	3.40M	1.52M	503.00K	1.09M
Interest Expense % of Total Revenue	2528.00%	3009.30%	2562.65%	717.09%	-	1948.05%	14442857.14%	4557.58%	-	8929.41%	2647.37%	-

Balance Sheet

Currency: EUR	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	3.09M	6.04M	2.87M	929.00K	4.52M	1.73M	10.65M	9.77M	5.24M	2.49M	3.41M	2.14M
Total Liabilities	9.33M	13.07M	5.35M	4.85M	7.13M	3.59M	2.96M	5.27M	6.51M	2.79M	1.79M	3.72M
Total Equity	-6.24M	-7.03M	-2.48M	-3.91M	-2.60M	-1.84M	7.71M	4.51M	-1.27M	-294.00K	1.61M	-1.58M
Cash	1.53M	4.09M	2.21M	622.00K	4.29M	1.39M	10.30M	9.46M	4.63M	2.25M	3.24M	2.01M
Total Debt	6.32M	8.88M	2.94M	2.60M	4.79M	129.00K	107.00K	2.44M	4.09M	1.17M	56.00K	2.39M
Net Debt	4.79M	4.79M	727.00K	1.98M	497.00K	-1.27M	-10.23M	-7.02M	-548.00K	-1.08M	-3.24M	376.00K

Cash Flow

Currency: EUR	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-12.46M	-13.48M	-8.99M	-4.24M	-4.00M	-4.29M	-5.22M	-12.38M	-12.14M	-5.63M	-4.63M	-3.42M
Investing Cash Flow	-41.00K	-8.00K	4.00K	124.00K	66.00K	-16.00K	-39.00K	-14.00K	-21.00K	-19.00K	-21.00K	8.00K
Financing Cash Flow	8.92M	16.06M	7.11M	2.52M	7.60M	1.40M	14.18M	11.50M	7.29M	3.27M	5.66M	2.18M
Capital Expenditure	47.00K	8.00K	21.00K	2.00K	9.00K	16.00K	39.00K	14.00K	21.00K	19.00K	16.00K	0
Free Cash Flow	-12.51M	-13.49M	-9.01M	-4.24M	-4.01M	-4.30M	-5.26M	-12.39M	-12.16M	-5.65M	-4.65M	-3.42M
FCF to OCF	100.38%	100.06%	100.23%	100.05%	100.23%	100.37%	100.75%	100.11%	100.17%	100.34%	100.35%	100.00%

Earnings

Report Date	Sep 27, 2016	Mar 31, 2017	Oct 30, 2017	Apr 30, 2018	Oct 11, 2018	Apr 12, 2019	Oct 24, 2019	Apr 22, 2020	Oct 29, 2020	Apr 28, 2021	Oct 26, 2021	Apr 22, 2022	Oct 26, 2022	Apr 24, 2023	Oct 18, 2024	Apr 25, 2025	Oct 30, 2025
EPS Estimate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EPS Actual	-5.50	-42.49	-6.71	-1.35	-1.70	-1.20	-0.19	0.09	-0.26	-0.11	-0.11	-0.11	-1146.92	-12.86	-0.12	-0.06	-0.02
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	After-hours	-	Pre-market	After-hours	Pre-market	After-hours	After-hours	Pre-market	-	After-hours	-	After-hours	After-hours	After-hours	-	-	-

Key Statistics & Ratios

Market Cap9.78M

Enterprise Value10.63M

Trailing P/E0.00

Forward P/E1.07

Price / Sales219.49

Price / Book6.15

EPS-0.03

Book Value-0.017

Revenue (TTM)27.00K

Gross Profit (TTM)27.00K

EBITDA-2.84M

Profit Margin0.00%

Operating Margin3425.93%

Return on Equity-18771.43%

Return on Assets-64.52%

Shares Outstanding94.99M

Shares Float91.52M

Beta0.76

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Dec 10, 2024409:305
Nov 28, 2023588:533
Jul 28, 20221:100